Biomedical Prevention Navigator - Biomedical Prevention, Infectious Diseases
About the job
- A Master's degree is required, although a combination of education and/or experience may substitute for the minimum education.
- Basic Life Support certification must be obtained within one month of the hire date, and online-only certifications without a skills assessment component are not sufficient.
- Basic Life Support certification from the American Heart Association or American Red Cross is acceptable.
- The employee must maintain HIPAA compliance and required skills and competencies.
- The employee must participate in staff trainings and meetings, continuing education, and cross-training programs according to established standards and Washington University policies.
- Assist clients as they move through the care delivery system, including scheduling PrEP and sexual wellness appointments, providing medication adherence and retention support, and following up with patients who have fallen out of services.
- Navigate patients through the financial aspects of receiving care by enrolling them in insurance and public benefits programs and assisting with billing resolution.
- Help eliminate barriers to services, including financial and transportation barriers, and provide referrals to social support services.
- Provide individually appropriate support, referrals, and education to adult clients who are potentially exposed to HIV or sexually transmitted infections.
- Complete all required documentation for Biomedical Prevention Navigation services.
- Assist with quality control and quality assurance tasks for the Washington University in St. Louis Biomedical Prevention Program.
- Support Biomedical Prevention data collection.
- Conduct HIV and sexually transmitted infection counseling and testing in the clinic, including handling and transporting blood and urine specimens.
- Recruit PrEP clients through community outreach and collaboration with community partners in the St. Louis region.
- Keep PrEP information up to date on the Washington University in St. Louis PrEP Program website.
- Support implementation of biomedical HIV prevention interventions, including PrEP and PEP, for identified populations by assisting with data collection and reporting.
- Provide teamwork, collaboration, and customer service in support of the program.
- Participate in quality improvement activities to ensure appropriate clinical outcomes.
- Perform other duties as assigned to support the Washington University in St. Louis Biomedical Prevention Program.
- Bilingual Spanish-speaking ability is preferred.
- Preferred skills include case management, clinical evaluations, community resources, computer literacy, effective written communication, family support, HIPAA compliance, oral communication, patient care, patient education, prevention programs, referral coordination, team collaboration, and team communication.
About the company
Wash U translates academic research into practical technologies and programs that address global challenges. The institution supports scholars through grants and partnerships to move discoveries from the lab into the public sector via entrepreneurship and technology transfer. Unlike many traditional research institutions, Wash U emphasizes a high level of financial transparency and leverages a historical connection to Nobel Laureates to foster a collaborative environment. Its goal is to use these shared visions and research initiatives to create a more equitable future and provide tangible benefits to society.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
1853
Simplify's Take
What believers are saying
- Bristol Myers Squibb launched a July 21, 2026 neuroscience collaboration funding six annual fellows/projects.
- FY26 produced 316 invention disclosures, 85 patents, 12 startups, and $24.4 million licensing revenue.
- WashU named Philip R.O. Payne chief health AI officer, accelerating clinical AI adoption.
What critics are saying
- EEOC sued Washington University on August 12, 2026 over retaliatory firing claims at Siteman.
- Undergraduate tuition hit $71,310 for 2026-27, intensifying affordability pressure and yield risk.
- NIH supplied $727 million in FY2025; federal grant shocks threaten WashU's research engine.
What makes Wash U unique
- WashU ranked ninth in Cure Innovation Index on May 29, 2026.
- WashU Medicine ranked No. 2 among U.S. medical schools for NIH funding.
- WashU startups attracted $1.7 billion in private-sector investment during the past year.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Company Match
Wellness Program
Mental Health Support
Parental Leave
Family Planning Benefits
Company News
HMN 2026: How A painless punch with a microneedle patch could detect kidney disease earlier. Kidney disease is silent in its early stages, progressing without symptoms until the disease is advanced. Researchers in the McKelvey School of Engineering at Washington University in St. Louis, in collaboration with researchers at WashU Medicine and Texas A&M University, have been developing a minimally invasive method to improve diagnosis at earlier stages. New research from the lab of Srikanth Singamaneni, the Lilyan & E. Lisle Hughes Professor in the Department of Mechanical Engineering & Materials Science, shows the early success of a microneedle patch that can be applied to the skin to quickly and safely capture biomarkers and accurately quantify them. The patch detected early signs of kidney injury and may one day support home or point-of-care monitoring without requiring refrigeration. Results of the research were published in Advanced Materials. It is the first study to show that encapsulating biomolecules on microneedles preserved their biological functions. A stable patch for early detection. The research team, which includes Yixuan Wang, a doctoral student in Singamaneni's lab, created microneedles coated with a metal-organic framework (MOF) that can sample interstitial fluid in the skin. The microneedles are coated with a material that forms a shell that detects and preserves antibodies to neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker of acute kidney injury. The MOF shell preserved the antibodies for up to four weeks at 50°C (122°F) without refrigeration. "This metal-organic framework encapsulation is a simple and highly effective way to create microneedle sensors that are resilient to environmental challenges and provide a scalable path to minimally invasive biosensing for at-home or remote health monitoring," Singamaneni said. NGAL increases in the blood within hours of a kidney injury and is a clinically validated biomarker for kidney damage. However, because it requires drawing blood with a needle and cold-chain logistics, it has not been useful in home-based or resource-limited settings. Overcoming the cold-chain barrier. Previously, Singamaneni and collaborators established another type of microneedle patches that can look for biomarkers of disease. Adapting that low-cost, easy-to-use technology required them to create a biosensor with high sensitivity and a broader range, as well as address cold-chain logistics. Publication details. Yixuan Wang et al, Metal-Organic Framework?Preserved Thermostable Microneedle Patch for Minimally Invasive Detection and Monitoring of Kidney Dysfunction, Advanced Materials (2026). DOI: 10.1002/adma.74423 Journal information: Advanced Materials NephrologyLaboratory medicine Provided by Washington University in St. Louis The content is provided for information purposes only.
WashU develops automotive-grade carbon fiber from lignin waste. Single-walled carbon nanotubes guide crystallite alignment in a lignin/PAN precursor that halves PAN use and, researchers report, reduces carbon fiber production costs by 25%. Senior Managing Editor, CompositesWorld and Products Finishing Microscopic "rebar" adds strength to a new kind of carbon fiber material that features functionalized single-walled carbon nanotubes. WashU engineers developed the manufacturing process to make use of lignin and to further strengthen carbon fiber for use in automotive and energy industries. Source | Yuan lab Researchers at Washington University in St. Louis (WashU, Mo., U.S.) have developed a lignin-based renewable carbon fiber that they say meets automotive standards for tensile strength and elastic modulus. It uses less petroleum-derived precursor and costs less to produce than conventional carbon fiber. The work, published in the journal Matter, could extend renewable carbon fiber into autocomposites and other carbon fiber-reinforced polymer (CFRP) applications. "For the first time, this allows us to create renewable carbon fiber that reaches the high standard of quality used in automobile manufacturing," says Joshua Yuan, Lucy & Stanley Lopata Professor and chair of energy, environmental and chemical engineering at WashU McKelvey Engineering, and director of the National Science Foundation (NSF) Carbon Utilization Redesign for Biomanufacturing (CURB) Engineering Research Center at WashU. Quadrupling U.S. Composites capacity. Six months after acquiring SHD, Cambium is standing up a 60,000-sq-ft rapid manufacturing center in Mooresville, N.C. Read the Article Sponsored by SHD Composites Key to the work is making use of a waste material called lignin, the second most abundant natural biopolymer on Earth. Lignin is produced as a byproduct of the paper pulping and biorefining industries, and ordinary disposal methods for lignin result in a substantial environmental footprint. WashU engineers wanted to see if they could use lignin to improve production methods for carbon fiber. The material is traditionally manufactured using synthetic polyacrylonitrile (PAN), a petroleum-derived product that is mixed with chemicals, spun through tiny jets into fibers, washed and stretched. This type of production process for carbon fiber is called "wet spinning." However, PAN is not cheap, accounting for up to 50% of the total manufacturing cost of carbon fiber, which limits its use to high-end products, Yuan notes. By adding affordable and abundant lignin to the process, the WashU team found that they could cut the use of PAN by half, reduce production costs by 25% and also cut carbon emissions substantially. However, the new carbon fiber product still needed to meet automotive standards for tensile strength and elastic modulus. So, researchers also developed another process that is said to greatly improves performance, involving the deployment of single-walled carbon nanotubes into the polymer matrix, which act almost like rebar in lining up the crystallization chemistry. This innovation revealed a new design principle for carbon fiber material development. "Crystallization alignment is critical for carbon fiber quality," Yuan says. The carbon nanotubes allowed WashU researchers to make a precursor solution of the lignin and PAN. Weiwei Li, a postdoctoral scholar in Yuan's lab and first author of the research, described this as a three-step process. "The first step was to create a nanotube template that can mix well with lignin and PAN and allows for high crystallization or orientation," Li explains. "Step two involves running that precursor solution through a wet spinning and tension-assisted heat treatment. Finally, one round of optimized carbonization fully strengthens the fiber. The three steps together maximize the crystallite content, while the carbon nanotubes guide the crystallite orientation to create rebar effects for high mechanical properties." Automotive is just the entry point for the optimized fiber, researchers believe. Everything from sports equipment to wind turbines offer equal potential. This research received support from the Lucy & Stanley Lopata Professorship and US Department of Energy Projects DE EE 0008250. Further support came from the Institute for Materials Science and Engineering (IMSE) and Chemical and Environmental Analysis Facility (CEAF) at WashU as well as the NSF CURB Engineering Research Center (NSF EEC 2330245).
WashU Medicine researchers at Siteman earn national recognition for leukemia research. By Siteman Communications Published: September 11, 2026 | Updated: September 11, 2026 Read time: 2 mins American Society of Hematology awards grants to Francesca Ferraro, Jaebok Choi Two WashU Medicine investigators at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, have been awarded prestigious grants from the American Society of Hematology (ASH), the world's largest professional society serving clinicians and scientists working to conquer blood diseases. Francesca Ferraro, MD, PhD, and Jaebok Choi, PhD, both assistant professors of medicine at WashU Medicine and research members at Siteman Cancer Center, each received an Award for Research Careers in Hematology (ARCH). The merit-based grants provide $150,000 in funding and may be used over one to three years. Separately, Ferraro and Choi study different strategies to improve treatments and outcomes for patients diagnosed with leukemia. They are among 33 awardees announced by ASH on Aug. 25. Collectively, their research is aimed and both hematologic malignancies, such as pediatric and adult leukemia, and benign conditions, including sickle cell disease and neonatal anemia. Together, WashU Medicine and Siteman Cancer Center are one of only four institutions to have two researchers named to the awardee list. "This group of researchers represents the best of the best, and their science has the potential to make a great difference in our understanding of hematologic conditions," said ASH President Robert Negrin, MD. "By investing in these researchers now, we are keeping critical science moving forward and making it clear that patients cannot be left waiting for progress." Ferraro, who treats patients diagnosed with acute myeloid leukemia (AML) and other blood cancers at Siteman Cancer Center, is researching cell mutations that contribute to the development and progression of AML. She and her lab aim to identify mutation-specific vulnerabilities that could be targeted in personalized approaches to improve the effectiveness of current chemotherapies. Choi focuses on graft-versus-host disease (GVHD), a serious complication where the immune cells of a stem cell donor attack a transplant recipient's healthy tissues. His research aims to identify novel genes that may be blocked genetically or with therapeutic drugs to prevent GvHD while maintaining or enhancing the benefits of stem cell transplantation. ASH counts more than 18,000 members from nearly 100 countries and hosts an annual conference that regularly highlights scientific and clinical advances of world-renowned WashU Medicine investigators at Siteman Cancer Center. The 68th ASH Annual Meeting and Exposition is Dec. 12-15 in New Orleans and will spotlight Ferraro and Choi and their newly funded research.
WashU Medicine marketing and communications wins five Telly Awards. August 28, 2026 A movie trailer, local TV spot and documentaries produced by WashU Medicine Marketing & Communications recently won five Telly awards, an international contest honoring excellence in TV and video production. The 47th annual competition recognizes creators, brands and production companies from national television networks, movie studios, major brands, sports teams and universities, among others. The organization received nearly 14,000 entries, a 6% increase from last year and the most ever. And the awards go to... * "In Our Lifetime - Part 1: A Piece of Me" follows a family burdened by inherited early-onset Alzheimer's disease and the hope they find in research led by WashU Medicine. The documentary received a silver award in the category Branded Content - Documentary: Short Form (Under 40 minutes). The team included (cinematographer and editor) Huy Mach, WashU Medicine senior video producer; (producer) Macallan Lay, project manager; (director) Josh Kell, assistant vice chancellor and executive creative director; and Jessica Church, director of media relations. * "Changing What's Possible" is a powerful, 30-second look into WashU Medicine's approach to advancing medicine. The commercial received a silver award in the Local TV Craft Writing category. Recipients were Jessy Lobel, senior creative director, and Kell. * "The Cure Within" documents the first patients in the region to receive a newly approved gene therapy for sickle cell disease and the WashU Medicine physicians who made the opportunity possible. The video won two bronze medals in the categories Branded Content - Documentary: Short Form (Under 40 minutes) and Branded Content - Science & Technology. Staff members involved were Mach, Kell, Church and senior sciences writer Marta Wegorzewska. * "Another Tomorrow" features patients whose lives were transformed by a drug for a genetic form of amyotrophic lateral sclerosis (ALS). Research led by WashU Medicine served as the basis for the drug's FDA approval. The trailer received a bronze in the category Film & Shorts - Movie Trailer. Winners were Mach, Lay, Kell and Church.
A painless punch with a microneedle patch could detect kidney disease earlier. Kidney disease is silent in its early stages, progressing without symptoms until the disease is advanced. Researchers in the McKelvey School of Engineering at Washington University in St. Louis, in collaboration with researchers at WashU Medicine and at Texas A&M University, have been developing a minimally invasive method to improve diagnosis in earlier stages. New research from the lab of Srikanth Singamaneni, the Lilyan & E. Lisle Hughes Professor in the Department of Mechanical Engineering & Materials Science, shows the early success of a microneedle patch that can be applied on the skin to quickly and safely capture biomarkers and quantify them accurately. The patch detected early signs of kidney injury and may one day support home or point-of-care monitoring without requiring refrigeration. Results of their research were published online Aug. 5 in Advanced Materials. It is the first study to show that encapsulating biomolecules on microneedles preserved their biological functions. The research team, which includes Yixuan Wang, a doctoral student in Singamaneni's lab, created microneedles coated with a metal-organic framework (MOF) that can sample interstitial fluid in the skin. The microneedles are coated with a material that creates a shell that detects and preserves neutrophil gelatinase-associated lipocalin (NGAL) antibodies, which are an early biomarker of acute kidney injury. The MOF shell preserved the antibodies for up to four weeks at 50 C (122 F) without refrigeration. "This metal-organic framework encapsulation is a simple and highly effective way to create microneedle sensors that are resilient to environmental challenges and provide a scalable path to minimally invasive biosensing for at-home or remote health monitoring," Singamaneni said. NGAL increases in the blood within hours of a kidney injury and is a clinically validated biomarker for kidney damage. However, because it requires drawing blood with a needle and cold-chain logistics, it has not been useful in home-based or resource-limited settings. Previously, Singamaneni and collaborators established another type of microneedle patches that can look for biomarkers of disease. Adapting that low-cost, easy-to-use technology required them to create a biosensor with high sensitivity and a broader range, as well as addressing cold-chain logistics. Wang Y, Liu Y, Debnath A, Li C, Want Z, Kondepati G, Balmoori S, Morrissey JJ, Chen YM, Tian L, Singamaneni S. Metal-Organic Framework-Preserved Thermostable Microneedle Patch for Minimally Invasive Detection and Monitoring of Kidney Dysfunction. Advanced Materials, published online Aug. 5, 2026. DOI: https://doi.org/10.1002/adma.74423 This research was supported by funding from the National Science Foundation (CBET 2224610 and CBET 560 2316285), the National Institutes of Health (R21DK131557A1, R35 GM147568, R01 2DK105056-6 and R56DK138158A1), the Congressionally Directed Medical Research Programs (HT94252310996 and W81XWH-19-1-0320), and VA Merit (I01BX006401A1). Singamaneni and Jeremiah J. Morrissey are the inventors of the plasmonic-fluor technology, which has been licensed by the Office of Technology Management at Washington University in St. Louis.